Many managers, when deciding to transition from .NET to Java, often carry the inherent belief that "Java's ecosystem is mature, and the talent pool is large," but overlook the essential technical ...

Gilead Sciences' TROP2-targeting drug Trodelvy is already used as a third-line treatment for PD-L1-positive triple-negative breast cancer (TNBC), but could be heading for use in previously untreated ...